Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
For Study 6, the primary efficacy parameters were mean percent change in body weight and the percentage of patients achieving greater than or equal to 5% weight loss from baseline to Week 68
Baseline laboratory testing is required for all patients entering the program
from ICSTF of SINH, CAS for technical assistance
hypothesis: may be no difference between the two populations
Clinical studies from 2025 show that post-surgical patients lose an average of 13.5% additional body weight when using GLP-1 agonists
Growth is also driven by the rise of telehealth consultations and digital prescriptions, enabling easier patient access to GLP-1 therapies without visiting physical stores
